Notably, γδ T cells are of increasing therapeutic interest, due partly to their potential to mount either anti-tumour,[47], [48], [49] or alternatively immunosuppressive50 responses, but also their MHC-unrestricted recognition of target cells, which raises the prospect of broad applicability of γδ T cell-based therapies in patient cohorts. Here, HLA-C is linked to neoplasm.